Literature DB >> 19476798

Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience.

Giovanni D Aletti1, Sean C Dowdy, Bobbie S Gostout, Monica B Jones, Robert C Stanhope, Timothy O Wilson, Karl C Podratz, William A Cliby.   

Abstract

BACKGROUND: After observing disparate rates of cytoreduction, we initiated efforts to improve outcomes through feedback and education, and we reassessed outcomes. STUDY
DESIGN: Outcomes from group A (2006 and 2007, n=105) were compared with those from the cohort predating quality-improvement efforts (group B, 2000 to 2003, n=132). All stage IIIC ovarian cancer patients at our institution were evaluated for tumor dissemination, age, performance status, surgical complexity, residual disease (RD), morbidity, and mortality. A surgical complexity score previously described was used to categorize extent of operation.
RESULTS: No significant differences in age, performance status, or extent of disease were observed between cohorts. Surgical complexity increased after initiation of quality improvement (mean surgical complexity score, 5.5 to 7.1; p < 0.001), rates of optimal RD (< 1 cm) improved from 77% to 85% (p=0.157), and rates of complete resection of all gross disease rose from 31% to 43% (p=0.188). In the subset of patients with carcinomatosis most likely to benefit from extended surgical resection, radical procedures were used more frequently (63% versus 79%; p=0.028), rates of optimal debulking (RD<1 cm) increased (64% to 79%), and the rate of RD=0 increased from 6% to 24% (p=0.006). When disease was noted on the diaphragm, procedures to remove the disease were more frequently used (38% to 64%; p=0.001). The rates of major perioperative morbidity (group B, 21% versus group A, 20%; p=0.819) and 3-month mortality (8% versus 6%; p=0.475) were not affected despite this more aggressive surgical approach.
CONCLUSIONS: Analysis of outcomes with appropriate feedback and education is a powerful tool for quality improvement. We observed improvements in rates of cytoreduction and use of specific radical procedures, with no increase in morbidity as a result of this process.

Entities:  

Mesh:

Year:  2009        PMID: 19476798     DOI: 10.1016/j.jamcollsurg.2009.01.006

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  24 in total

Review 1.  The impact of feedback of surgical outcome data on surgical performance: a systematic review.

Authors:  Mahiben Maruthappu; Abhishek Trehan; Ashton Barnett-Vanes; Peter McCulloch; Matthew J Carty
Journal:  World J Surg       Date:  2015-04       Impact factor: 3.352

2.  Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer.

Authors:  Rudy S Suidan; Mario M Leitao; Oliver Zivanovic; Ginger J Gardner; Kara C Long Roche; Yukio Sonoda; Douglas A Levine; Elizabeth L Jewell; Carol L Brown; Nadeem R Abu-Rustum; Mary E Charlson; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2015-05-31       Impact factor: 5.482

3.  Clinical research device for ovarian cancer detection by optical spectroscopy in the ultraviolet C-visible.

Authors:  Ronie George; Archana Chandrasekaran; Molly A Brewer; Kenneth D Hatch; Urs Utzinger
Journal:  J Biomed Opt       Date:  2010 Sep-Oct       Impact factor: 3.170

4.  Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells.

Authors:  Xiaoping He; Takayo Ota; Peng Liu; Changqing Su; Jeremy Chien; Viji Shridhar
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

5.  Surgical debulking of ovarian cancer: what difference does it make?

Authors:  John O Schorge; Christopher McCann; Marcela G Del Carmen
Journal:  Rev Obstet Gynecol       Date:  2010

6.  Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer.

Authors:  Edward J Tanner; Kara C Long; Qin Zhou; Rachel M Brightwell; Ginger J Gardner; Nadeem R Abu-Rustum; Mario M Leitao; Yukio Sonoda; Richard R Barakat; Alexia Iasonos; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2012-04-13       Impact factor: 5.482

7.  Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for ovarian cancer.

Authors:  Valerie B Galvan-Turner; Jenny Chang; Argyrios Ziogas; Robert E Bristow
Journal:  Gynecol Oncol       Date:  2015-09-24       Impact factor: 5.482

Review 8.  Review of methodological challenges in comparing the effectiveness of neoadjuvant chemotherapy versus primary debulking surgery for advanced ovarian cancer in the United States.

Authors:  Ashley L Cole; Anna E Austin; Ryan P Hickson; Matthew S Dixon; Emma L Barber
Journal:  Cancer Epidemiol       Date:  2018-05-25       Impact factor: 2.984

9.  Laparoscopy for primary cytoreduction with multivisceral resections in advanced ovarian cancer: prospective validation. "The times they are a-changin"?

Authors:  Marcello Ceccaroni; Giovanni Roviglione; Francesco Bruni; Roberto Clarizia; Giacomo Ruffo; Matteo Salgarello; Michele Peiretti; Stefano Uccella
Journal:  Surg Endosc       Date:  2017-10-19       Impact factor: 4.584

Review 10.  Considerations in the surgical management of ovarian cancer in the elderly.

Authors:  Carrie Langstraat; William A Cliby
Journal:  Curr Treat Options Oncol       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.